Jinxin Fertility Group Insiders Placed Bullish Bets Worth CN¥5.59m

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Jinxin Fertility Group Limited (HKG:1951), it sends a favourab

Simply Wall StJun 17 21:20 ET

HKEX News | JXR (01951) up more than 5% in the afternoon, encouraging childbirth and assisted reproduction are continuously catalyzed by the inclusion of medical insurance policies.

Shares of Jxr (01951) rose more than 5% this afternoon. As of press time, it rose 4.61% to HKD 3.18 with a trading volume of HKD 29.177 million.

Zhitong FinanceJun 13 01:51 ET

HK stocks surge | JXR (01951) rises nearly 6%, domestic policies continue to catalyze, and the assisted reproduction industry is expected to rebound in business activity.

According to the app of Zhitong Finance, JXR (01951) rose nearly 6%, rising 5.96% to HKD 3.38 as of press time, with a turnover of HKD 54.93 million. In order to implement positive fertility support measures, the Shanghai Medical Insurance Bureau, together with the Human Resources and Social Security and Health Departments, issued the "Notice on Including Some Therapeutic Assisted Reproductive Technology Projects in the Scope of Medical Insurance and Work Injury Insurance Payment", which will include 12 assisted reproductive medical services projects in the scope of medical insurance payment. It will be implemented from June 1, 2024. According to incomplete statistics, as of now, Beijing, Guangxi, Inner Mongolia

Zhitong FinanceJun 4 03:00 ET

錦欣生殖：股東週年大會通告

Hong Kong Stock ExchangeMay 31 06:12 ET · Announcements

Retail Investors Among Jinxin Fertility Group Limited's (HKG:1951) Largest Stockholders and Were Hit After Last Week's 8.2% Price Drop

Key Insights The considerable ownership by retail investors in Jinxin Fertility Group indicates that they collectively have a greater say in management and business strategy The top 25 shareholders

Simply Wall StMay 30 18:21 ET

[Broker Focus] CITIC Construction Investment maintains Jinxin Reproduction (01951) “buy” rating. Looking at the short term, relevant policies will increase the penetration rate of assisted reproductive technology

Jinwu Financial News | According to CITIC Construction Investment Securities Research, Jinxin Production (01951) achieved revenue of 2,789 million yuan in 2023, up 18% year on year; net profit of 347 million yuan, up 194% year on year; adjusted net profit of 472 million yuan, up 72% year on year; and basic earnings per share of 0.13 yuan/share. According to the bank, the company's 2023 performance is in line with expectations, and demand for assisted reproductive technology and services has resumed. Looking ahead to 2024, domestic policies to encourage childbearing and the inclusion of assisted reproduction in health insurance will continue to be catalyzed, and industry sentiment is expected to pick up further; the company will use Chengdu as a model to create assisted reproduction

金吾財訊May 30 03:26 ET